Adobe Flash Player is required to view this content.

Welcome to HemaCare Corporation – a leading global provider of biological blood products and services since 1978.

HemaCare Corporation is a blood services company serving healthcare providers and the scientific community for over 30 years. HemaCare and its subsidiary, Coral Blood Services, perform therapeutic apheresis services, provide human-derived biological products, and support the implementation of cellular therapy based trials with apheresis collections. Learn more

RESEARCH PRODUCTS

HemaCare provides a variety of human primary blood cells such as lymphocytes, monocytes, neutrophils, CD34+ and CD133+ stem cells, serum and much more!

  • Normal donor subjects and patients
  • Normal and mobilized peripheral blood
  • Apheresis and whole blood derived

Human Peripheral Blood

Human Peripheral Blood

 

 

CELLULAR THERAPY

Quality of living cellular raw material is a major determinant of final product characteristics. Controlling and qualifying the cell collection step is essential to minimizing operational sources of variability, and greatly increases the likelihood of success in manufacturing. HemaCare’s specialty is apheresis collection, and, building on over 30 years of experience, has addressed this need for optimized cell collection with a program for controlling and qualifying its apheresis procedures and collection sites, bringing a higher degree of reproducibility to research projects or manufacturing efforts based on cGMP and cGTP principles.

Sourcing Human Blood-Derived Raw Material: Optimization, Qualification and Control
Click here to view the presentation

THERAPEUTIC APHERESIS SAMPLE ORDER FORMS

ANNOUNCEMENTS

News

Thu, 10 May 2012 13:41:49 GMT

Terumo BCT to Invest in State-of-the-Art Facilities in the U.S. and Vietnam

Mon, 07 May 2012 13:00:38 GMT

Millennium and Seattle Genetics Initiate Global Phase 3 Trial of ADCETRIS in Patients with CD30-Expressing Relapsed Cutaneous T-cell Lymphoma

Mon, 07 May 2012 11:25:05 GMT

Idera Pharmaceuticals Announces Efficacy Data for IMO-8400 in Preclinical Models of Lupus and Psoriasis

Thu, 03 May 2012 18:33:26 GMT

Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argos's Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks

Tue, 01 May 2012 21:25:43 GMT

Study Using Stem Cell Therapy Shows Promise in Fight Against HIV

Tue, 01 May 2012 04:00:48 GMT

Researchers at UPMC, Stanford test stem cells to enhance stroke recovery

Mon, 30 Apr 2012 11:20:17 GMT

Sangamo BioSciences Nominates Saira Ramasastry To The Company’s Board Of Directors

Fri, 20 Apr 2012 00:57:40 GMT

The Leukemia & Lymphoma Society Congratulates Carl June, MD of University of Pennsylvania for Award for Work in Immunotherapy

Thu, 19 Apr 2012 13:36:12 GMT

Stanford Scientists Show Lab-Made Heart Cells Ideal For Disease Research, Drug Testing

Tue, 17 Apr 2012 19:58:40 GMT

Northwest Bio Welcomes New Additions to the Board of Directors

Tue, 17 Apr 2012 18:38:59 GMT

Stem Cell Agency Unveils Strategic Partnership Award To Increase Industry Investment In Research

Fri, 13 Apr 2012 13:25:59 GMT

Immunovaccine Inc. Named

Thu, 12 Apr 2012 05:55:55 GMT

Lonza and Agennix Sign Development and Manufacturing Deal for Production of Talactoferrin

Wed, 11 Apr 2012 13:29:20 GMT

NeoStem Announces the Addition of Jonathan Sackner-Bernstein, MD, Past FDA Official, as Vice President, Clinical Development and Regulatory Affairs

Wed, 11 Apr 2012 11:19:24 GMT

SeraCare Expands the AccuCell Line with Human Cord Blood Mononuclear Cells

 

Events

3.2.2012 HemaCare will be attending the International Society for Cellular Therapy (ISCT) Annual Meeting taking place June 5 – 8, 2012 in Seattle, WA and presenting our presentation entitled Sourcing Biologic Materials and Managing Supply Chains – Quality Considerations.  For more information on the meeting, please visit www.celltherapysociety.org.

 

More News & Events

 

E-NEWSLETTER SIGN UP